XPhyto Therapeutics to Acquire German Narcotics Company

大麻公司XPhyto Therapeutics收购德国麻醉药品制造商Vektor Pharma

2019-08-29 16:06:00 CFN Media Group

本文共1435个字,阅读需4分钟

XPhyto Therapeutics Corp. is pleased to announce that it has entered into a definitive share purchase agreement with Vektor Pharma TF GmbH , a German narcotics manufacturer, to acquire 100% of the issued and outstanding shares. XPhyto has also entered into an equipment purchase agreement with an affiliated company to purchase thin film drug delivery manufacturing equipment. Vektor is a German-based narcotics company focused on the research, development and production of therapeutic films for pharmaceuticals, cosmetics and food. The company has established itself as an expert in the design, testing and manufacture of thin film drug delivery systems, including transdermal patches and sub-lingual (oral) strips. Vektor also holds a number of valid narcotics licences pursuant to EU GMP certification and other governing regulations: Import Permit for drug dosage forms; Import Permit for cannabis; Manufacturing Permit for clinical samples; Manufacturing Permit for final drug product release; Analytical Permit for chemical and physical testing; Permit to handle narcotic drugs; and a Permit to handle animal tissue. Vektor’s various narcotics licences include authorizations related to conventional and cannabis-related prescription medications, including but not limited to: Buprenorphine, cannabis, Dronabinol, Fentanyl, Hydromorphone, Oxycodone, and THC. “XPhyto is building a next generation cannabis company focused on medical formulation, clinical validation and emerging European markets,” said Hugh Rogers, CEO of XPhyto. “We believe that Vektor will add significant long-term value at every level of our business, from clinical trial expertise and drug manufacturing capability to their German cannabis and narcotics import licences and strong relationships with the German health authority.” Pursuant to the Agreement and the Equipment Agreement, the consideration is as follows: 1) 350,000 € cash due upon closing; 2) 200,000 common shares due upon closing; 3) 400,000 € units in the capital of the Company at CAD $1.00 per unit (the “Payment Units”) due upon closing. Each Payment Unit consists of one common share and one common share purchase warrant. The common shares are subject to a three-year escrow matrix. The warrants are exercisable into one common share of the Company at an exercise price of CAD $1.00 per share for a period of three years from closing; 4) 200,000 € in a convertible debenture with a maturity date that is six months from closing bearing an annual interest rate of 2.5%. The debenture is convertible into Payment Units at the option of the holder, at any time prior to the maturity date. Accrued interest will be paid in cash. Each common share purchase warrant is exercisable into one common share at an exercise price of CAD $1.00 per share for a period of three years from the conversion date; and 5) 150,000 € in a convertible debenture with a maturity date that is twelve months from closing bearing an annual interest rate of 2.5%. The debenture is convertible into Payment Units at the option of the holder, at any time prior to the maturity date. Accrued interest will be paid in cash. Each common share purchase warrant is exercisable into one common share at an exercise price of CAD $1.00 per share for a period of three years from the conversion date. Pricing of the securities set out in the Agreement and Equipment Agreement was established pursuant to a price reservation filed with the Canadian Securities Exchange on August 6, 2019, and a non-binding letter of intent signed August 7, 2019. The acquisition remains subject to certain regulatory approvals and closing conditions, and if satisfied, is expected to close on or about September 16, 2019. In connection with the transaction, a consulting fee of 200,000 common shares will be paid to an arms-length consultant on closing. About XPhyto Therapeutics Corp. XPhyto is a science-based cannabis company focused on medical formulation, clinical validation, and emerging European markets. XPhyto’s 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM). XPhyto is pursuing additional opportunities in Germany including cultivation, processing, manufacturing, import, and distribution. In Canada, two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified extraction, isolation, and formulation facilities, drug research and development expertise, as well as commercial analytical testing capability.
XPhyto Therapeutics Corp .高兴地宣布,它已与德国麻醉药品制造商 Vektor Pharma TF GmbH 签订最终股份购买协议,收购已发行和已发行股份的100%。XPhyto 还与一家关联公司签订了设备采购协议,购买薄膜药物递送制造设备。 维克托是一家德国麻醉药品公司,专注于药品、化妆品和食品的治疗膜的研发和生产。公司已建立了自己的专家在设计,测试和制造薄膜药物输送系统,包括透皮贴片和亚语(口腔)条。维克多还根据欧盟 GMP 认证和其他管理法规持有多个有效的麻醉药品许可证:药品剂型进口许可证;大麻进口许可证;临床样品制造许可证;最终药品放行制造许可证;化学和物理检测分析许可证;麻醉药品处理许可证;以及动物组织处理许可证。维克多的各种麻醉药品许可证包括与常规和大麻相关的处方药相关的授权,包括但不限于:布丙诺啡、大麻、 Droptinol 、芬太尼、氢吗啡酮、 Oxychado 和 THC 。 “ XPhyto 正在打造一家专注于医疗制剂、临床验证和新兴欧洲市场的下一代大麻公司,” XPhyto 首席执行官休•罗杰斯( Hugh Rogers )表示。“我们相信,维克托将在我们的每一个业务层面上增加重大的长期价值,从临床试验专业知识和药品制造能力,到德国大麻和麻醉品进口许可证,以及与德国卫生当局的密切关系。” 根据该协议及设备协议,代价如下:1)350,000欧元于交割时到期的现金;2)200,000股于交割时到期的普通股;3)400,000欧元于交割时按每股1.00加元(下称“支付单位”)计算的本公司资本单位。每个支付单元由一个普通股和一个普通股购买权证组成。普通股服从三年托管矩阵。认股权证可于收市后三年内按行使价每股1.00加元行使为本公司一股普通股;4)200,000欧元可换股债券,到期日为收市后六个月,年利率为2.5%。债券可在到期日之前的任何时间由持有人选择转换为支付单位。应计利息将以现金支付。每股普通股购买认股权证可于转换日起三年内按行使价每股1.00加元行使为一股普通股;及5)150,000欧元可换股债券,到期日为自收市起十二个月,年利率为2.5%。债券可在到期日之前的任何时间由持有人选择转换为支付单位。应计利息将以现金支付。每股普通股购买认股权证可于转换日起三年内按行使价每股 CAD $1.00行使为一股普通股。 根据于2019年8月6日向加拿大证券交易所提交的价格保留意见及于2019年8月7日签署的不具约束力的意向书,确定协议及设备协议所载证券的定价。 本次收购事项尚需取得一定的监管批准和交割条件,如满足,预计将于2019年9月16日或前后完成。 就该交易而言,200,000股普通股的咨询费将于交易结束时支付给一名独立顾问。 关于 XPhyto Therapeutics Corp 。 XPhyto 是一家以科学为基础的大麻公司,专注于医药制剂、临床验证和新兴欧洲市场。XPhyto 拥有100%股权的德国子公司 Bunker Pfranzenkatekte GmbH 已获得德国联邦药物和医疗器械研究所( BfArM )颁发的用于科学目的的独特的德国大麻种植和提取许可证。XPhyto 正在德国寻求更多的机会,包括种植、加工、制造、进口和分销。在加拿大,与加拿大一所主要大学的药剂系进行了两次为期5年的独家合作,提供了经认证的提取、隔离和制剂设施、药物研发专业知识以及商业分析测试能力。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文